Table 1 Characteristics of included studies
Study | Diagnosis (criteria for diagnosis) | Treatment(s) | Treatment duration, weeks | Inclusion criteria |
|---|---|---|---|---|
Randomized controlled trials | ||||
Findling et al. 2012 [21] | Schizophrenia (DSM-IV-TR + K-SADS-PL) | Quetiapine 400 mg/day Quetiapine 800 mg/day Placebo | 6 | Inpatients or outpatients aged 13–17 years; PANSS ≥ 60 |
Findling et al. 2008 [22] | Schizophrenia (DSM-IV) | Aripiprazole 10 mg/day Aripiprazole 30 mg/day Placebo | 6 | Aged 13–17 years; PANSS ≥ 70 |
Haas et al. 2009a [23] | Schizophrenia (DSM-IV + K-SADS-PL) | Risperidone 1–3 mg/day Risperidone 4–6 mg/day Placebo | 6 | Aged 13–17 years; PANSS 60–120 |
Haas et al. 2009b [26] | Schizophrenia (DSM-IV + K-SADS-PL) | Risperidone 1.5–6 mg/day Risperidone 0.15–0.6 mg/day | 8 | Aged 13–17 years; PANSS 60–120 |
Kryzhanovskaya et al. 2009 [24] | Schizophrenia (DSM-IV-TR) | Olanzapine 2.5–20 mg/day Placebo | 6 | Aged 13–17 years; BPRS ≥ 35 |
Singh et al. 2011 [25] | Schizophrenia (DSM-IV + K-SADS-PL) | Paliperidone 1.5 mg/day Paliperidone 3–6 mg/day Paliperidone 6–12 mg/day Placebo | 6 | Aged 12–17 years; Weight ≥ 29 kg; PANSS 60–120 |
Observational studies | ||||
Duval et al. 2008 [27] | Schizophreniform disorder (DSM-IV) | Risperidone 1–6 mg/day | 3 | Aged 14–18 years |
Kumra et al. 2008 [28] | Schizophrenia, schizoaffective disorder (K-SADS-PL) | Clozapine 25–900 mg/day Olanzapine 30 mg/day | 12 | Aged 10–18 years |
Pandina et al. 2012 [29] | Schizophrenia (DSM-IV + K-SADS-PL) | Risperidone 2–6 mg/daya | 24 or 48a | Aged 13–17 years; PANSS 40–120 |
Ruan et al. 2010 [30] | Schizophrenia (DSM-IV-TR) | Risperidone 25–50 mg biweekly | 24 | Aged 13–18 years; PANSS ≤ 80 |
Schimmelmann et al. 2007 [31] | Schizophrenia, schizoaffective and schizophreniform disorder (DSM-IV) | Quetiapine 200–800 mg/day | 12 | Aged 12–17 years; PANSS ≥ 60 |